(NASDAQ: RANI) Rani Therapeutics Holdings's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.
Rani Therapeutics Holdings's earnings in 2026 is -$29,442,000.On average, 6 Wall Street analysts forecast RANI's earnings for 2026 to be -$24,330,596, with the lowest RANI earnings forecast at -$26,709,148, and the highest RANI earnings forecast at -$22,113,093. On average, 6 Wall Street analysts forecast RANI's earnings for 2027 to be -$27,167,514, with the lowest RANI earnings forecast at -$29,137,252, and the highest RANI earnings forecast at -$26,015,404.
In 2028, RANI is forecast to generate -$26,226,004 in earnings, with the lowest earnings forecast at -$30,351,304 and the highest earnings forecast at -$20,812,323.